MedinCell Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Christophe Douat
Chief executive officer
€781.5k
Total compensation
| CEO salary percentage | 38.0% |
| CEO tenure | 10.4yrs |
| CEO ownership | n/a |
| Management average tenure | 3.9yrs |
| Board average tenure | less than a year |
Recent management updates
Recent updates
Industry Analysts Just Made An Incredible Upgrade To Their MedinCell S.A. (EPA:MEDCL) Revenue Forecasts
Dec 25
MedinCell S.A. (EPA:MEDCL) Analysts Are More Bearish Than They Used To Be
Jul 05Revenues Tell The Story For MedinCell S.A. (EPA:MEDCL) As Its Stock Soars 30%
Apr 26Market Participants Recognise MedinCell S.A.'s (EPA:MEDCL) Revenues Pushing Shares 26% Higher
Jan 09The MedinCell (EPA:MEDCL) Share Price Is Up 75% And Shareholders Are Holding On
Mar 02Is MedinCell S.A. (EPA:MEDCL) Popular Amongst Insiders?
Jan 08CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -€31m |
| Jun 30 2024 | n/a | n/a | -€28m |
| Mar 31 2024 | €782k | €297k | -€25m |
| Dec 31 2023 | n/a | n/a | -€26m |
| Sep 30 2023 | n/a | n/a | -€26m |
| Jun 30 2023 | n/a | n/a | -€29m |
| Mar 31 2023 | €522k | €267k | -€32m |
| Dec 31 2022 | n/a | n/a | -€29m |
| Sep 30 2022 | n/a | n/a | -€27m |
| Jun 30 2022 | n/a | n/a | -€26m |
| Mar 31 2022 | €329k | €258k | -€25m |
| Dec 31 2021 | n/a | n/a | -€22m |
| Sep 30 2021 | n/a | n/a | -€20m |
| Jun 30 2021 | n/a | n/a | -€19m |
| Mar 31 2021 | €336k | €235k | -€19m |
| Dec 31 2020 | n/a | n/a | -€22m |
| Sep 30 2020 | n/a | n/a | -€26m |
| Jun 30 2020 | n/a | n/a | -€25m |
| Mar 31 2020 | €301k | €232k | -€24m |
| Dec 31 2019 | n/a | n/a | -€21m |
| Sep 30 2019 | n/a | n/a | -€19m |
| Jun 30 2019 | n/a | n/a | -€19m |
| Mar 31 2019 | €244k | €192k | -€20m |
| Dec 31 2018 | n/a | n/a | -€17m |
| Sep 30 2018 | n/a | n/a | -€15m |
| Jun 30 2018 | n/a | n/a | -€12m |
| Mar 31 2018 | €175k | €149k | -€10m |
Compensation vs Market: Christophe's total compensation ($USD811.64K) is above average for companies of similar size in the French market ($USD540.83K).
Compensation vs Earnings: Christophe's compensation has increased whilst the company is unprofitable.
CEO
Christophe Douat (58 yo)
10.4yrs
Tenure
€781,528
Compensation
Mr. Christophe Douat has been the Chief Executive Officer of MedinCell S.A and serves as its Director since September 12, 2024. He served as Chairman of the Management Board at MedinCell S.A until Septembe...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer & Director | 10.4yrs | €781.53k | no data | |
| Chief People Officer & Member of the Management Board | 4.7yrs | €383.09k | no data | |
| Chief Financial Officer | 1.3yrs | no data | no data | |
| Chief Operating Officer | no data | no data | no data | |
| General Counsel & Chief Corporate Development Officer | 3.9yrs | no data | no data | |
| Head of Corporate & Financial Communications and ESG | no data | no data | no data | |
| Head of Research & Development | no data | no data | no data | |
| Chief Business Officer | 2.9yrs | no data | no data | |
| Head of Global Health Development | 8.1yrs | no data | no data | |
| Chief Medical Officer | 2.7yrs | no data | no data | |
| Head of Pharmaceutical Operations | no data | no data | no data | |
| Senior Communications Officer | no data | no data | no data |
3.9yrs
Average Tenure
Experienced Management: MEDCL's management team is considered experienced (3.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer & Director | less than a year | €781.53k | no data | |
| Director | less than a year | €25.00k | no data | |
| Director | less than a year | €26.50k | no data | |
| Chairman of the Board | less than a year | €28.00k | no data | |
| Director | less than a year | €25.00k | no data | |
| Censor | no data | no data | no data | |
| Independent Vice Chairman | less than a year | €21.00k | no data |
0.3yrs
Average Tenure
58yo
Average Age
Experienced Board: MEDCL's board of directors are not considered experienced ( 0.3 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 20:29 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
MedinCell S.A. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alexandru Cogut | Bryan Garnier & Co |
| Oscar Haffen Lamm | Bryan Garnier & Co |
| Raghuram Selvaraju | H.C. Wainwright & Co. |